Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
- Tool Weighs Benefits, Risks of Raloxifene or Tamoxifen to Prevent Breast Cancer
(Posted: 06/14/2011) - Researchers have developed a benefit-risk index to help guide decisions on whether postmenopausal women at increased risk of developing breast cancer should take raloxifene or tamoxifen to reduce that risk.
- Eribulin Improves Survival of Women with Metastatic Breast Cancer
(Posted: 06/10/2011) - Treatment with eribulin (Halaven™) improved overall survival in women with metastatic breast cancer whose disease progressed despite multiple rounds of prior chemotherapy, according to the results of a phase III clinical trial called EMBRACE.
- Denosumab Effective for Multiple Myeloma and Solid Tumors
(Posted: 06/08/2011) - Results from a randomized phase III trial of denosumab to prevent skeletal related events in several types of cancer were published online February 22, 2011, in the Journal of Clinical Oncology (JCO).
- Chemotherapy Regimen Extends Survival in Advanced Pancreatic Cancer Patients
(Posted: 06/07/2011) - A four-drug chemotherapy regimen has produced the longest improvement in survival ever seen in a phase III clinical trial of patients with metastatic pancreatic cancer, one of the deadliest types of cancer.
- Five Years of Tamoxifen Continues to Benefit Women 15 Years after Treatment
(Posted: 06/03/2011) - In a large randomized clinical trial, women with early-stage breast cancer who received 5 years of adjuvant treatment with tamoxifen had better outcomes up to 15 years after the start of treatment than those who received 2 years of tamoxifen therapy.